¼¼°èÀÇ Àç»ý¿ä¹ý ½ÃÀå
Regenerative Therapies
»óǰÄÚµå : 1793774
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 287 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,245,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,736,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àç»ý¿ä¹ý ¼¼°è ½ÃÀåÀº 2030³â±îÁö 174¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 112¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Àç»ý¿ä¹ý ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 7.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 174¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼¼Æ÷ Ä¡·á´Â CAGR 9.2%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 78¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áٱ⼼Æ÷ Ä¡·á ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 30¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Àç»ý¿ä¹ý ½ÃÀåÀº 2024³â¿¡ 30¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 38¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.8%¿Í 7.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Àç»ý¿ä¹ý ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Àç»ý¿ä¹ýÀÌ ÀÇ·áÀÇ ¹Ì·¡¸¦ ¹Ù²Ù´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Àç»ý¿ä¹ýÀº Áúº´À̳ª ¼Õ»óµÈ ¼¼Æ÷, Á¶Á÷, Àå±â¸¦ º¹±¸, ´ëü, Àç»ýÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϴ ÷´Ü ÀÇ·áÀÇ Çõ½ÅÀû ºÐ¾ßÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº Áٱ⼼Æ÷, Á¶Á÷°øÇÐ, À¯ÀüÀÚ ÆíÁý, »ýü°øÇÐ ¹°ÁúÀ» Ȱ¿ëÇÏ¿© ½ÅüÀÇ ÀÚ¿¬ Ä¡À¯ °úÁ¤À» ÀÚ±ØÇÕ´Ï´Ù. ±âÁ¸ Ä¡·á´Â Áõ»óÀ» ¾ïÁ¦Çϰųª Áúº´ÀÇ ÁøÇàÀ» ¸·´Â °æ¿ì°¡ ¸¹¾ÒÁö¸¸, Àç»ý¿ä¹ýÀº »ý¹°ÇÐÀû ±â´ÉÀ» ¿ÏÀüÈ÷ ȸº¹½ÃŰ·Á´Â °ÍÀÔ´Ï´Ù. ±× Àû¿ë ¹üÀ§´Â Á¤Çü¿Ü°úÀû ¼Õ»ó, ½ÉÇ÷°üÁúȯ, ½Å°æ ÅðÇ༺ Áúȯ, ÀÚ°¡ ¸é¿ª Áúȯ, ½ÉÁö¾î Àå±â Àç»ý¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù.

Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á¹ý, ƯÈ÷ °£¿±Áٱ⼼Æ÷(MSCs)´Â ¿¬°ñ Àç»ý, »óó Ä¡À¯, ÇãÇ÷¼º Áúȯ¿¡ ÀÖ¾î ÃÖÀü¼±¿¡ ¼­ ÀÖ½À´Ï´Ù. Áٱ⼼Æ÷´Â ¸é¿ªÁ¶Àý ÀÛ¿ëÀ» ³ªÅ¸³»¸ç ¿©·¯ Á¶Á÷ÇüÀ¸·Î ºÐÈ­ÇÒ ¼ö ÀÖ¾î ±× À¯¿ë¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÇÑÆí, Àΰø¸¸´ÉÁٱ⼼Æ÷(iPSC)´Â ¸é¿ª°ÅºÎ¹ÝÀÀÀÇ À§ÇèÀ» ÁÙÀÎ ÀÚ°¡Ä¡·á¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À½ºÄ¿Æúµù°ú 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃÀÇ ¹ßÀüÀº ƯÈ÷ Á¤Çü¿Ü°ú ¹× Àç°Ç ÀÇ·á ºÐ¾ß¿¡¼­ ±¸Á¶ÀûÀ¸·Î ½ÇÇà °¡´ÉÇÑ Á¶Á÷À» ±¸ÃàÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¸¸¼ºÁúȯÀ» ¼¼Æ÷ ¹× ºÐÀÚ ¼öÁØ¿¡¼­ ´Ù·ç°Ô µÇ´Â ÆÐ·¯´ÙÀÓÀÇ ÀüȯÀ» °¡Á®¿À°í ÀÖ½À´Ï´Ù.

»õ·Î¿î ±â¼ú°ú Ç÷§ÆûÀº ¾î¶»°Ô ÀÓ»óÀû È¿°ú¸¦ ³ôÀ̰í Àִ°¡?

ÀÌ ºÐ¾ß´Â À¯ÀüÀÚ ÆíÁý ¼¼Æ÷ Ä¡·á, ±â¼ºÇ° µ¿Á¾ ÀÌ½Ä Ç÷§Æû, Á¤¹ÐÀÇ·áÀÇ ÅëÇÕÀ¸·Î ±Þ¼ÓÇÑ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. CRISPR/Cas9 ¹× ¿°±â±³Á¤ ±â¼úÀº È¿°ú¿Í ³»±¸¼ºÀ» ³ôÀ̱â À§ÇØ Àç»ý ÇÁ·ÎÅäÄÝ¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Á¶Ç÷¸ð¼¼Æ÷ ÆíÁýÀº °â»ó ÀûÇ÷±¸ºóÇ÷À̳ª º£Å¸ ÁöÁßÇØºóÇ÷°ú °°Àº Ç÷¾×ÁúȯÀÇ ÀáÀçÀû Ä¡·á¹ýÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¢¼ÒÁ»À» Æ÷ÇÔÇÑ ¼¼Æ÷¿Ü¼ÒÆ÷ü ¿¬±¸ÀÇ ¹ßÀüÀº »ý¼¼Æ÷¿Í °ü·ÃµÈ À§Çè ¾øÀÌ Àç»ý °¡´É¼ºÀÌ ÀÖ´Ù´Â Á¡¿¡¼­ ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À Á¦Á¶´Â ÀÚµ¿È­, Æó¼âÇü ·çÇÁ ½Ã½ºÅÛ, ÀϰüµÈ Á¦Ç° ǰÁúÀ» À§ÇÑ È®Àå °¡´ÉÇÑ Ç÷§ÆûÀ¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ¸ðµâ½Ä Ŭ¸°·ë, ·Îº¿½Ä ¼¼Æ÷¹è¾ç ½Ã½ºÅÛ, GMP¿¡ ÁØÇÏ´Â ³Ãµ¿º¸°ü ±â¼ú·Î ºñ¿ëÀ» Àý°¨ÇÏ°í »ê¾÷Àû È®À强À» È®º¸ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. AI¿Í ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº ȯÀÚº° ¿À¹Í½º µ¥ÀÌÅ͸¦ ºÐ¼®Çϰí, Àç»ý¿ä¹ý¿¡ ´ëÇÑ ¹ÝÀÀÀ» ¿¹ÃøÇϰí, ÀÓ»ó½ÃÇè ¼³°è¸¦ °£¼ÒÈ­Çϱâ À§ÇØ µµÀԵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úµéÀº ƯÈ÷ ´Ù¹ß¼º °æÈ­ÁõÀ̳ª 1Çü ´ç´¢º´°ú °°Àº ÀÌÁú¼ºÀÌ ³ôÀº Áúȯ¿¡¼­ ½ÅÁ¦Ç°ÀÇ ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇϰí Ä¡·á Á¤È®µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ö¿ä¸¦ ÁÖµµÇÏ´Â Ä¡·á ¿µ¿ª°ú Àü´Þ ¸ðµ¨Àº?

Á¤Çü¿Ü°ú ¹× ±Ù°ñ°Ý°è ÀÀ¿ë ºÐ¾ß, ƯÈ÷ ¿¬°ñ º¹±¸, ÈûÁÙ Àç»ý, ô¼ö ¼Õ»ó¿¡ ´ëÇÑ ÀÀ¿ë ºÐ¾ß°¡ ÇöÀç ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP) ¹× Áٱ⼼Æ÷ ÁÖ»ç´Â ÃÖ¼Òħ½ÀÀûÀ̰í ȸº¹À» ÃËÁøÇÑ´Ù´Â Áõ°Å·Î ÀÎÇØ ½ºÆ÷Ã÷ ÀÇÇÐ ¹× ½Åü ÀçȰ¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü°è Àç»ý¿ä¹ý ½ÉºÎÀüÀ̳ª ÇãÇ÷¼º »çÁö »óÅ¿¡ ´ëÇÑ ½É±Ù¼¼Æ÷ ´ëü, Ç÷°ü Àç»ý µî ½ÉÇ÷°ü°èµµ Ȱ±â¸¦ ¶ì°í ÀÖ½À´Ï´Ù. ½Å°æÁúȯ, ƯÈ÷ ³úÁ¹Áß, ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´Àº °­·ÂÇÑ ¿¬±¸ ÆÄÀÌÇÁ¶óÀÎÀ» °¡Áø ½ÅÈï ºÐ¾ßÀÔ´Ï´Ù.

ÀÇ·á Á¦°ø ¸ðµ¨Àº ÀÔ¿ø ÁßÀÎ º´¿ø ȯ°æ¿¡¼­ ¿Ü·¡ Áø·á¼Ò, ¿Ü·¡ Àç»ý¿ä¹ý¼¾ÅÍ, Àü¹® Á¤Çü¿Ü°ú Ŭ¸®´ÐÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ»êÈ­´Â POC(Point-of-Care) Á¦Á¶¿Í ¼ÒÇüÈ­µÈ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ÅøÀÇ ¹ßÀüÀ¸·Î µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. µ¿Á¾ ¼¼Æ÷ÀºÇàÀº º¸´Ù ºü¸¥ Àü´Þ Áֱ⸦ °¡´ÉÇÏ°Ô Çϰí ÀÚ°¡ Á¶Á÷ äÃë¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß°í ÀÖ½À´Ï´Ù. µ¿¹ÝÁø´Ü, ½Ç½Ã°£ ¿µ»ó Áø´Ü, ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÅëÇÑ Åõ¾à Àü·«Àº Ä¡·á ¼º°ú¿Í ¸ð´ÏÅ͸µÀ» ´õ¿í ÃÖÀûÈ­Çϰí ÀÖ½À´Ï´Ù. Áø´ÜÇÐ, Àç»ý »ýüÀç·á, µðÁöÅÐ Çコ ÅøÀÇ À¶ÇÕÀº º¸´Ù Æ÷°ýÀûÀ̰í ÀûÀÀ·ÂÀÌ ³ôÀº Àü´Þ »ýŰ踦 °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

Àç»ý¿ä¹ý ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Àç»ý¿ä¹ý ½ÃÀåÀÇ ¼ºÀåÀº ¹ÌÃæÁ·µÈ ÀÓ»óÀû ¼ö¿ä, °í·ÉÈ­ Àα¸±¸Á¶, ¿ìÈ£ÀûÀÎ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, °ø°ø ¹× ¹Î°£ ÅõÀÚ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¸¸¼ºÁúȯ, ³ëÈ­¿¡ µû¸¥ ÅðÇ༺ Áúȯ, ¿Ü»ó µîÀº ±âÁ¸ÀÇ Ä¡·á¹ýÀ¸·Î´Â ÃæºÐÈ÷ ´ëóÇÒ ¼ö ¾ø¾î Ä¡·áÀû ¶Ç´Â ±â´É ȸº¹Àû °³ÀÔ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Àα¸ °í·ÉÈ­°¡ ÁøÇàµÇ¸é¼­ °ñ°üÀý¿°, ½ÉÇ÷°üÁúȯ, ½Å°æ ÅðÇ༺ Áúȯ¿¡ ´ëÇÑ Àç»ý¿ä¹ýÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ FDAÀÇ RMAT(Regenerative Medicine Advanced Therapy) ÁöÁ¤°ú À¯·´ÀÇ ATMP(Advanced Therapy Medicines) ±ÔÁ¦ °æ·Î¿Í °°Àº Á¤Ã¥Àû ÇÁ·¹ÀÓ¿öÅ©´Â ½ÂÀÎ ÀýÂ÷¸¦ °¡¼ÓÈ­Çϰí Çõ½Å¿¡ ´ëÇÑ Àμ¾Æ¼ºê¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ö½Ê¾ï ´Þ·¯ÀÇ º¥Ã³ Àڱݰú ¹Î°ü ÆÄÆ®³Ê½ÊÀÌ ÀÓ»ó½ÃÇè, ¿¬±¸ ÀÎÇÁ¶ó, ¹ÙÀÌ¿À Á¦Á¶ÀÇ ½ºÄÉÀϾ÷¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. NIH, CIRM(͏®Æ÷´Ï¾Æ Àç»ýÀÇÇבּ¸¼Ò), ÀϺ»ÀÇ AMED¿Í °°Àº ±â°üµéÀÌ Àü ¼¼°è ¿¬±¸°³¹ßÀÇ ±â¼¼¸¦ ¿Ã¸®°í ÀÖ½À´Ï´Ù. À¯È¿¼º°ú °¡°Ý ¹®Á¦°¡ ÇØ°áµÇ´Â ÇÑ, Àç»ý¿ä¹ýÀº Æ´»õ Çõ½Å¿¡¼­ ºÎ´ã½º·¯¿î Ä¡·á ¿µ¿ª Àü¹ÝÀÇ ÁÖ·ù Ä¡·á·Î ÀüȯÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(¼¼Æ÷ Ä¡·á, Áٱ⼼Æ÷ Ä¡·á, Á¶Á÷°øÇÐ Ä¡·á, À¯ÀüÀÚ Ä¡·á), ¿ëµµ(»óó Ä¡·á, ±Ù°ñ°Ý°è, Á¾¾çÇÐ, Ä¡°ú, µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ , °£Áúȯ, ¿°Áõ¼º¡¤ÀÚ°¡¸é¿ªÁúȯ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Regenerative Therapies Market to Reach US$17.4 Billion by 2030

The global market for Regenerative Therapies estimated at US$11.2 Billion in the year 2024, is expected to reach US$17.4 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Cell Therapy, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$7.8 Billion by the end of the analysis period. Growth in the Stem Cell Therapy segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 12.3% CAGR

The Regenerative Therapies market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 12.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Regenerative Therapies Market - Key Trends & Drivers Summarized

Why Are Regenerative Therapies Reshaping the Future of Medicine?

Regenerative therapies represent a transformative segment within advanced medicine, aiming to repair, replace, or regenerate diseased or damaged cells, tissues, or organs. These therapies leverage stem cells, tissue engineering, gene editing, and bioengineered materials to stimulate the body’s natural healing processes. Unlike conventional treatments that often manage symptoms or halt disease progression, regenerative therapies attempt to restore full biological function. Their applications extend across orthopedic injuries, cardiovascular diseases, neurodegenerative disorders, autoimmune diseases, and even organ regeneration.

Stem cell-based therapies, particularly mesenchymal stem cells (MSCs), remain at the forefront, especially in cartilage regeneration, wound healing, and ischemic diseases. They exhibit immunomodulatory effects and can differentiate into multiple tissue types, enhancing their utility. Meanwhile, induced pluripotent stem cells (iPSCs) are driving forward autologous treatments with reduced risk of immune rejection. Additionally, advancements in bio-scaffolding and 3D bioprinting are enabling structurally viable tissue constructs, especially in orthopedic and reconstructive medicine. These innovations are ushering in a paradigm shift where chronic ailments are increasingly addressed at a cellular and molecular level.

How Are Emerging Technologies and Platforms Enhancing Clinical Efficacy?

The field is undergoing rapid innovation through gene-edited cell therapies, off-the-shelf allogeneic platforms, and precision medicine integration. CRISPR/Cas9 and base editing technologies are being integrated into regenerative protocols to enhance efficacy and durability. For instance, editing hematopoietic stem cells is emerging as a potential cure for blood disorders like sickle cell anemia and beta-thalassemia. Furthermore, advancements in extracellular vesicle research, including exosomes, are gaining traction for their regenerative potential without the risks associated with live cells.

Biomanufacturing is evolving through automation, closed-loop systems, and scalable platforms for consistent product quality. Modular cleanrooms, robotic cell culture systems, and GMP-compliant cryopreservation techniques are reducing costs and enabling industrial scalability. AI and machine learning algorithms are being deployed to analyze patient-specific omics data, predict response to regenerative treatments, and streamline clinical trial design. These technologies are reducing time-to-market for new products and increasing therapeutic precision, particularly in diseases with high heterogeneity such as multiple sclerosis or Type 1 diabetes.

Which Therapeutic Areas and Delivery Models Are Driving Market Demand?

Orthopedic and musculoskeletal applications dominate current market usage, particularly in cartilage repair, tendon regeneration, and spinal cord injury. Platelet-rich plasma (PRP) and stem cell injections are widely used in sports medicine and physical rehabilitation due to their minimally invasive nature and evidence of enhanced recovery. Cardiovascular regenerative therapies are also gaining momentum, including myocardial cell replacement and vascular regeneration for heart failure and ischemic limb conditions. Neurological disorders-particularly stroke, Parkinson’s disease, and ALS-are emerging areas with a robust research pipeline.

Delivery models are expanding beyond inpatient hospital settings to include ambulatory clinics, outpatient regenerative therapy centers, and specialized orthobiologic practices. This decentralization is supported by advances in point-of-care manufacturing and miniaturized bioprocessing tools. Allogeneic cell banks are enabling faster delivery cycles and reduced dependency on autologous tissue harvesting. Companion diagnostics, real-time imaging, and biomarker-guided dosing strategies are further optimizing therapeutic outcomes and monitoring. The convergence of diagnostics, regenerative biomaterials, and digital health tools is enabling a more holistic and adaptive delivery ecosystem.

What Factors Are Driving the Growth of the Regenerative Therapies Market?

The growth in the regenerative therapies market is driven by unmet clinical needs, aging demographics, supportive regulatory frameworks, and increased investment from public and private sectors. Chronic diseases, age-related degeneration, and traumatic injuries remain inadequately addressed by conventional therapies, creating a persistent demand for curative or function-restoring interventions. Aging populations in North America, Europe, and parts of Asia-Pacific are also contributing to the need for regenerative solutions in osteoarthritis, cardiovascular disease, and neurodegeneration.

Policy frameworks such as the U.S. FDA’s RMAT (Regenerative Medicine Advanced Therapy) designation and Europe’s ATMP (Advanced Therapy Medicinal Products) regulatory pathway are expediting approval processes and incentivizing innovation. Additionally, billions of dollars in venture funding and public-private partnerships are fueling clinical trials, research infrastructure, and biomanufacturing scale-up. Institutions like the NIH, CIRM (California Institute for Regenerative Medicine), and Japan’s AMED are catalyzing global R&D momentum. As long as efficacy and affordability challenges are addressed, regenerative therapies are poised to move from niche innovation to mainstream treatment across high-burden therapeutic areas.

SCOPE OF STUDY:

The report analyzes the Regenerative Therapies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Cell Therapy, Stem Cell Therapy, Tissue engineering Therapy, Gene Therapy); Application (Wound Care Application, Musculoskeletal Application, Oncology Application, Dental Application, Duchenne Muscular Dystrophy Application, Hepatological Diseases Application, Inflammatory & Autoimmune Diseases Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â